Search

A 90-minute ASM Health webinar about the proposed Phage Therapy Coordination Platform is scheduled for October 27, 2026, at 9:30 a.m. ET. Via Pittsburgh Phage Program — exact Bluesky announcement. ASM Health

Ottignies-Louvain-La-Neuve, Belgium As a Chief Medical Officer, you will be accountable for Inteliphage’s medical strategy and for the clinical development of its Phage Therapy Medicinal Product (PTMP) portfolio. You will convert an advanc

npj Viruses is inviting submissions to its collection “Phages as antimicrobial therapy”, edited by Ruby CY Lin (The University of Sydney), Sabrina Green (KU Leuven) and Renee Ng (The Kids Research Institute Australia and The University of W

ESCMID scheduled an in-person postgraduate course and hands-on phage-therapy workshop at Tbilisi State Medical University and the George Eliava Institute for May 11–13, 2026. The program included lectures, case discussions and laboratory wo

Terminated. Checked 2026-10-03. This study hopes to demonstrate the potentials of a new form of therapy for childhood diarrhea, a major cause of morbidity and deaths in Bangladesh and other developing countries, and thus a priority for impr

Conflicting status. Checked 2026-10-03. The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for dia

Status unconfirmed. Individual-case protocol. Checked 2026-10-03. This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of bacteriophage therapy to treat and prevent the recurrence of a drug-resistant urina

Status unconfirmed. Checked 2026-10-03. DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site inf

Recruiting. Checked 2026-10-03. This is a Phase 1b study to assess the safety, tolerability, PK, and PD of investigational phage therapy (IP) in adults with SCI and bladder colonization (ASB). It is a single-center, randomized, double-blind

Not yet recruiting. Checked 2026-10-03. Total joint replacements are effective for chronic pain but can lead to Prosthetic Joint Infections (PJI), primarily caused by Staphylococcus aureus and resistant to antibiotics. Standard treatment in

Expanded access. Individual-case protocol. Checked 2026-10-03. This is a single patient study (SPS) that aims to test the bacteriophage treatment as an experimental treatment on a patient suffering from chronic periprosthetic joint infectio

Active, not recruiting. Individual-case protocol. Checked 2026-10-03. This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Morganell

Not yet recruiting. Checked 2026-10-03. The purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial inf

Recruiting. Checked 2026-10-03. The goal of this clinical trial is to learn if a new treatment called AchromoPhage is safe and well tolerated in adults with cystic fibrosis (CF) who have long-term lung infections caused by Achromobacter bac

Not yet recruiting. Checked 2026-10-03. This study is an investigator-initiated, single-center, exploratory clinical trial designed to evaluate the safety and efficacy of phage therapy in patients with urinary tract infections caused by dru

Not yet recruiting. Individual-case protocol. Checked 2026-10-03. This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Staphylococcu

Not yet recruiting. Checked 2026-10-03. Total joint replacement (TJR) has revolutionized care provided for patients suffering from disabling joint pain. Unfortunately, periprosthetic joint infection (PJI) remains a devastating complication